期刊
JOURNAL OF CELLULAR BIOCHEMISTRY
卷 119, 期 1, 页码 81-94出版社
WILEY
DOI: 10.1002/jcb.26165
关键词
CRISPR-Cas9; sgRNA; DSB; NHEJ; HDR; INDELS; THERAPEUTIC
资金
- Puri Foundation for Education in India
- C.V. Raman International Fellowship [INT/NAI/CVRF/2014]
The Type II CRISPR-Cas9 system is a simple, efficient, and versatile tool for targeted genome editing in a wide range of organisms and cell types. It continues to gain more scientific interest and has established itself as an extremely powerful technology within our synthetic biology toolkit. It works upon a targeted site and generates a double strand breaks that become repaired by either the NHEJ or the HDR pathway, modifying or permanently replacing the genomic target sequences of interest. These can include viral targets, single-mutation genetic diseases, and multiple-site corrections for wide scale disease states, offering the potential to manage and cure some of mankind's most persistent biomedical menaces. Here, we present the developing progress and future potential of CRISPR-Cas9 in biological and biomedical investigations, toward numerous therapeutic, biomedical, and biotechnological applications, as well as some of the challenges within. J. Cell. Biochem. 119: 81-94, 2018. (c) 2017 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据